Three categories of muscle-building compound. Different mechanisms, different legal status, different safety trade-offs. Peptides win on some axes and lose on others — this article lays out where each category fits and where it falls short, so a serious decision about training pharmacology is made with real information, not marketing.
Short answer on raw muscle-building power: steroids > SARMs > peptides. Short answer on safety, legality, and long-term sustainability: peptides > SARMs > steroids. The right pick depends on your priorities — and on what you will actually stick with for the next decade.
The Three Categories in One Table
| Axis | Peptides (GH stacks) | SARMs | Steroids |
|---|---|---|---|
| Typical first-cycle muscle gain | 2-4 lb | 5-8 lb | 10-20 lb |
| Strength increase | Modest | Moderate | Large |
| Recovery improvement | Large | Moderate | Large |
| HPTA suppression | None | Yes (moderate) | Yes (severe) |
| Liver toxicity | None | Moderate (some) | Moderate-severe (orals) |
| Lipid disruption | Minimal | Moderate | Severe |
| Cardiac remodeling | None documented | Unclear | Yes (long-term) |
| Legal status (US) | Research chemical / Rx | Unscheduled but unapproved | Controlled substance |
| Requires PCT | No | Yes | Yes |
| Typical cycle cost (12 wk) | $400-700 | $200-400 | $150-300 |
| Bloodwork cadence | Quarterly | Monthly | Biweekly (orals) |
Peptides: Mechanism and Reality
Growth hormone peptide stacks — tesamorelin + ipamorelin, CJC-1295 + ipamorelin, sermorelin + ipamorelin — work by amplifying the body's own pulsatile GH release through two receptors simultaneously. A GHRH analog primes the pituitary somatotrophs; a GHRP triggers release through the ghrelin receptor. Combined, they produce a GH pulse 2-3x larger than either alone (Bowers et al., 1990).
The downstream effect: elevated IGF-1, improved recovery, modest lean mass gains, reduced visceral fat. Tesamorelin's phase III trials showed 15-18% visceral fat reduction and preserved muscle cross-sectional area (Falutz et al., 2010; Adrian et al., 2019). Realistic first-cycle gain in a trained lifter: 2-4 lb of lean tissue over 12-16 weeks.
What peptides don't do: put 20 lb on you in a cycle. The GH/IGF-1 axis has a physiological ceiling that bounds the total muscle-building effect. If the goal is the physique transformation of a first steroid cycle, peptides will disappoint.
Non-GH peptides worth mentioning:
- Follistatin-344 — myostatin inhibitor, mechanism distinct from GH (Kota et al., 2009 in nonhuman primates). Experimental.
- IGF-1 LR3 — direct IGF-1 receptor agonist, advanced stack, hypoglycemia risk.
- BPC-157 and TB-500 — healing peptides, routinely stacked with heavier cycles for joint and tendon protection.
Deep dive: Best Tesamorelin + Ipamorelin Vendors | Best CJC-1295 + Ipamorelin Vendors — pre-mixed GHRH+GHRP blends ranked by price and COA.
SARMs: What They Actually Are
Selective androgen receptor modulators bind the androgen receptor like testosterone but with tissue-selective activation — designed to hit muscle strongly while sparing prostate and liver. The theory does not fully hold up in practice.
Common SARMs:
- Ostarine (MK-2866) — mildest, used in cutting cycles
- LGD-4033 (ligandrol) — strongest on mass, significant HPTA suppression
- RAD-140 (testolone) — strong, hepatotoxic signals in multiple reports
- YK-11 — technically a myostatin inhibitor with SARM-like activity, liver and cardiovascular concerns
- Cardarine (GW-501516) — PPAR-delta agonist, not technically a SARM, carcinogenicity signals in animal studies
Bloodwork reality on SARMs: HDL drops 30-50% within 4-6 weeks. Testosterone and LH suppress on most SARMs within 2 weeks. Liver enzymes elevate on RAD-140 and YK-11. The "safer than steroids" framing is marketing; the bloodwork patterns are closer to mild oral steroids than to supplements.
Quality issue: independent testing of SARM products sold as research chemicals repeatedly finds mislabeled compounds, incorrect dosing, or contamination. Unlike peptides sold by vendors with third-party COAs, the SARM market has minimal quality infrastructure.
Legal status (US): SARMs are not FDA-approved for human use and are technically illegal to sell for human consumption, though research chemical loopholes persist. WADA bans all SARMs for competitive athletes.
Cycle cost: $200-400 for 12 weeks plus $100-150 for PCT (SERMs like tamoxifen or enclomiphene to restart the HPTA).
Steroids: Mechanism and Real Trade-Offs
Anabolic-androgenic steroids — testosterone, nandrolone, trenbolone, oxandrolone, and dozens of derivatives — are the gold standard for maximum muscle-building, used by competitive bodybuilders, strength athletes, and TRT patients. No peptide or SARM matches them on raw mass or strength.
Typical first cycle (testosterone enanthate, 500 mg/week, 12 weeks): 10-20 lb of lean mass, 15-30% strength increase on compound lifts, dramatic improvement in recovery. Post-cycle, about 40-60% of gains are kept long-term with proper training.
Side-effect reality — what bloodwork actually shows:
- HDL drops 30-60% within 4-6 weeks
- Hematocrit and hemoglobin rise (cardiac workload)
- Blood pressure rises (variable, often 10-20 mmHg systolic)
- Estradiol rises proportional to dose and aromatase activity (requires aromatase inhibitor management)
- Full HPTA shutdown within 2-4 weeks
- Oral steroids (anadrol, oxandrolone, dianabol) add liver enzyme elevation
Long-term concerns: Multi-cycle users show cardiac remodeling on echocardiogram, accelerated atherosclerosis, and a small but real mortality signal in cohort studies of elite bodybuilders.
Legal status (US): Controlled substances under federal law. Possession without a prescription is a federal offense. TRT prescriptions are available for diagnosed hypogonadism but cycle-level doses are not.
Cycle cost: $150-300 for a 12-week test cycle + $100-200 for PCT + $50-150 for ancillaries (aromatase inhibitor, liver support for orals). Cheapest per cycle, most expensive in long-term bloodwork and cardiac cost.
